A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
235 patients around the world
Available in Spain, Brazil, United States
DBTP- Double blind treatment period (24 weeks) ETP - Extension treatment period (28
weeks) OLTP- Open label treatment period (68 weeks) Off-treatment follow up period (52
weeks)
